Ranibizumab
- Generic Name
- Ranibizumab
- Brand Names
- Byooviz, Cimerli, Lucentis, Susvimo, Ranivisio, Rimmyrah, Ximluci
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 347396-82-1
- Unique Ingredient Identifier
- ZL1R02VT79
- Background
Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment directed against human vascular endothelial growth factor A (VEGF-A), which is a glycoprotein implicated in the pathophysiology of age-related macular degeneration. Ranibizumab is used to treat various ocular disorders with abnormal growth of blood vessels, such as neovasc...
- Indication
Ranibizumab injection for intravitreal use is indicated to treat Neovascular (wet) Age-related Macular Degeneration (AMD), macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.
...
- Associated Conditions
- Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Macular Edema, Myopic Choroidal Neovascularization, Neovascular Age-Related Macular Degeneration (nAMD)
- Associated Therapies
- -
Effect of Ranibizumab on Malignant Conjunctival Neoplasia
- First Posted Date
- 2007-04-05
- Last Posted Date
- 2017-07-21
- Lead Sponsor
- The New York Eye Cancer Center
- Target Recruit Count
- 5
- Registration Number
- NCT00456495
- Locations
- ๐บ๐ธ
The New York Eye Cancer Center, New York, New York, United States
A Study of Strontium90 Beta Radiation With Lucentis to Treat Age-Related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2007-03-30
- Last Posted Date
- 2011-07-27
- Lead Sponsor
- NeoVista
- Target Recruit Count
- 494
- Registration Number
- NCT00454389
- Locations
- ๐บ๐ธ
Southeast Retina Center, Augusta, Georgia, United States
๐บ๐ธPaducah Retinal Center, Paducah, Kentucky, United States
๐บ๐ธRetina Research Unit of Wills Eye Hospital, Philadelphia, Pennsylvania, United States
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
- Conditions
- Interventions
- First Posted Date
- 2007-03-08
- Last Posted Date
- 2016-08-26
- Lead Sponsor
- Jaeb Center for Health Research
- Target Recruit Count
- 333
- Registration Number
- NCT00445003
- Locations
- ๐บ๐ธ
University of Illinois at Chicago Medical Center, Chicago, Illinois, United States
๐บ๐ธBay Area Retina Associates, Walnut Creek, California, United States
๐บ๐ธSoutheast Retina Center, P.C., Augusta, Georgia, United States
Study Comparing 0.5mg of Ranibizumab and Higher Doses in the Treatment of Clinically Significant Diabetic Macular Edema
- Conditions
- Interventions
- First Posted Date
- 2007-02-27
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Philip J. ferrone, M.D.
- Target Recruit Count
- 50
- Registration Number
- NCT00440609
- Locations
- ๐บ๐ธ
Long Island Vitreoretinal Consultants, Hauppauge, New York, United States
Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization
- Conditions
- Interventions
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2011-04-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 321
- Registration Number
- NCT00436553
- Locations
- ๐บ๐ธ
Novartis Investigative SIte, Royal Oak, Michigan, United States
๐จ๐ฆIvey Eye Institute, Dr. Thomas Sheidow, London, Ontario, Canada
๐บ๐ธWest Coast Retina Medical Group Inc. - 185 Berry St. Suite 130, San Francisco, California, United States
Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
- Conditions
- Interventions
- First Posted Date
- 2007-02-09
- Last Posted Date
- 2011-04-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 255
- Registration Number
- NCT00433017
- Locations
- ๐ฌ๐ง
Novartis Investigative site, Manchester, United Kingdom
The Ranibizumab for Edema of the mAcula in Diabetes-2 (READ-2) Study
- Conditions
- Interventions
- First Posted Date
- 2006-12-05
- Last Posted Date
- 2017-03-31
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 126
- Registration Number
- NCT00407381
- Locations
- ๐บ๐ธ
East Bay Retina Consultants, Oakland, California, United States
๐บ๐ธRetina Institute of California, Pasadena, California, United States
๐บ๐ธNew England Retina Consultants, PC, West Springfield, Massachusetts, United States
Lucentis for Central Retinal Vein Occlusion (CRVO)
- First Posted Date
- 2006-12-04
- Last Posted Date
- 2013-12-12
- Lead Sponsor
- California Retina Consultants
- Target Recruit Count
- 20
- Registration Number
- NCT00406796
- Locations
- ๐บ๐ธ
California Retina Consultants, Santa Maria, California, United States
Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2006-11-03
- Last Posted Date
- 2009-02-09
- Lead Sponsor
- The National Retina Institute
- Target Recruit Count
- 20
- Registration Number
- NCT00395707
- Locations
- ๐บ๐ธ
National Retina Institute, Towson, Maryland, United States
Safety Study of Ranibizumab Eye Injections to Treat Choroidal Neovascularization That Was Caused Other Than by Age-Related Macular Degeneration.
- First Posted Date
- 2006-11-03
- Last Posted Date
- 2010-01-08
- Lead Sponsor
- Ophthalmic Consultants of Boston
- Target Recruit Count
- 30
- Registration Number
- NCT00395551
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.